Seed Round · ₹4.5 Crore

Precision cancer diagnostics,
built fully in-house.

A vertically integrated molecular oncology laboratory in South India. IHC, FISH, qPCR, Sanger, targeted NGS, liquid biopsy, hereditary panels and comprehensive genomic profiling — every test on our own platform.

  • ₹4.5 CrSeed ask
  • 58–65%Gross margin
  • M20–22EBITDA break-even
  • Month 8NABL accredited
Investor snapshot
  • LocationHyderabad · Bangalore · Chennai
  • SectorPrecision oncology diagnostics
  • Model100% in-house, single-sequencer lab
  • Yr-3 revenue₹21.84 Cr
  • Yr-3 EBITDA₹8.60 Cr · 39%
  • Next round₹12–18 Cr Series A (Yr 3)
Scroll
01 — The Problem

Genomic testing is the bottleneck in Indian cancer care.

Cancer care has moved to precision medicine — but diagnostics infrastructure hasn't kept pace.

~1.5 Mn

new cancer cases in India annually; ~70% diagnosed at advanced stages where genomic testing is required.

3–4×

higher average revenue per test for advanced oncology assays vs. routine pathology.

~150

labs in India hold CAP certification as of 2026; fewer still run a full precision-oncology menu in-house.

7–14 days

typical turnaround time for ship-out NGS samples — delaying treatment decisions for oncologists.

The gap: A locally responsive, fully in-house precision-oncology lab that runs every assay on-site — eliminating ship-out delays, controlling quality end-to-end, and capturing the full margin on molecular testing.
02 — The Solution

A fully integrated in-house molecular oncology lab.

Every test — from sample receipt to oncologist-ready report — performed on our own platform.

🧬

Complete in-house menu

IHC, FISH, qPCR, Sanger, targeted and broad NGS, liquid biopsy, hereditary cancer panels, TMB, MSI, HRR and comprehensive genomic profiling — no ship-out for any test.

⚡

Fast turnaround

3–5 days for NGS vs. 7–10+ days for ship-out labs. 24 hours for IHC and qPCR. Faster TAT is a structural oncologist-acquisition advantage.

🎯

Full QC control

LIMS-driven QC gates at every step — extraction, library prep, sequencing, variant calling, reporting. Monthly re-run budgets embedded in COGS.

💰

Margin retained end-to-end

In-house COGS at 35–42% of revenue delivers 58–65% gross margin vs. ~50–52% for ship-out lab models.

1Sample receipt & accessioning
2Tissue processing · macro/microdissection
3Automated nucleic acid extraction
4Library prep · IHC / FISH / qPCR in parallel
5Sequencing (mid-throughput NGS)
6Bioinformatics · variant calling · ACMG
7Oncologist-ready report
03 — Market Opportunity

Large, growing, and structurally shifting toward molecular testing.

Segment2026 EstimateForecastCAGR
India cancer diagnostics (overall)USD 4.56 Bn (2024)USD 8.12 Bn by 203010.2%
India tumour biomarker assayUSD 320–380 MnUSD 1.1–1.5 Bn by 203514–17%
Liquid biopsy share12–15%18–22% by 2035Fastest-growing
NGS comprehensive profiling share18–22%25–30% by 2035Cost deflation

SAM — Serviceable Addressable Market

Targeting breast, lung, colorectal and haematological cancers in South India (Hyderabad, Bangalore, Chennai corridors) and referring Tier 2 cities. These cancers carry established biomarker guidelines and the largest molecular testing demand.

SOM — Serviceable Obtainable Market

Year-3 target of 650–800 tests/month — less than 1% of national biomarker testing volume, but a concentrated, high-value position in the South India private oncology market.

05 — Business Model & Unit Economics

In-house COGS lifts gross margin to 58–65%.

Revenue mix (Year 3)

Self-pay / out-of-pocket
55–60%
Hospital / oncologist referrals
25–30%
Insurance / CGHS / ECHS
10–15%
Pharma / CRO partnerships
5–10%

Unit economics (blended)

MetricValue
Average revenue per test₹28,000
Direct cost per test (in-house)₹9,800
Gross margin per test₹18,200 (65%)
Logistics + counselling₹600
Contribution margin / test₹17,600 (63%)
06 — Financial Projections

Three-year P&L — break-even at Month 20–22.

₹ Lakh. Base case with a phased volume ramp and NABL accreditation at Month 8.

Line Item (₹ Lakh)Year 1Year 2Year 3
Tests per month (avg.)80275650
Annual test volume9603,3007,800
ARPT (₹)26,00027,00028,000
Revenue249.6891.02,184.0
Direct costs (COGS)104.8338.6764.4
Gross profit144.8552.41,419.6
Gross margin58%62%65%
Manpower90.0168.0280.0
Rent & utilities24.036.048.0
Marketing & doctor engagement24.054.096.0
Accreditation, QA, legal15.018.024.0
Other admin, logistics, cloud12.034.0112.0
Total opex165.0310.0560.0
EBITDA(20.2)242.4859.6
EBITDA margin-8%27%39%
₹4.5 CrSeed round
₹2.97 CrLab capex
₹1.23 CrWorking capital buffer
Month 20–22EBITDA break-even
07 — Go-to-Market

Oncologist-anchored launch, Tier 2 expansion, pharma contracts.

Phase 1 · Months 0–12

Oncology Ecosystem Anchoring

  • Lab build, validation, NABL pathway (Months 1–8)
  • 20–30 medical oncologists across 8–10 private hospitals
  • Tumour board participation + CME-accredited sessions
  • TAT guarantee: 3–5 days NGS, 24 hrs IHC/qPCR
Phase 2 · Months 12–24

Tier 2 Expansion

  • Franchise / partner collection centres in Tier 2 cities
  • Genetic counselling tele-support for spoke patients
  • Insurance empanelment: CGHS, ECHS, private insurers
  • Sample cold-chain logistics
Phase 3 · Months 24–36

Pharma & CRO Partnerships

  • Companion diagnostic testing for targeted therapy launches
  • Real-world evidence generation with Indian pharma
  • CAP accreditation for international contract research
  • WGS and methylation profiling as volumes support
08 — Competition & Moat

Differentiated vs. national reference labs through local responsiveness.

Player TypeExamplesOur Advantage
National reference labsMedGenome, Strand, MetropolisLocally responsive, faster TAT, direct oncologist relationship, single-owner QC
Hospital-integrated labsTertiary cancer centresServe multiple hospitals; no single-hospital dependency
Routine pathology chainsRegional labsMolecular oncology depth, NGS + CGP + counselling
Ship-out / outsourced labsSmall regional labsWe capture the full margin and control turnaround
Defensible moat: Single-sequencer in-house model captures the margin that ship-out labs pay to third parties; oncologist relationship density in South India; genetic counselling layer; 3–5 day NGS turnaround is a structural differentiator.
09 — Team & Advisors

Deep in-house science capability is the core asset.

RoleProfileTiming
Founder / CEODiagnostics or healthcare operations background; South India oncology networkAt inception
Molecular Pathologist / Lab DirectorMD Pathology with molecular oncology experience; NABL signatoryAdvisory Yr 1, full-time Yr 2
NGS Scientists (2)MSc/PhD with Illumina or MGI library prep + sequencing experienceMonth 3–4
BioinformaticianVariant calling, annotation, ACMG classification, LIMS integrationMonth 4–5
Head of Sales (Oncology)Existing relationships with 50+ oncologists in South IndiaMonth 1–3
Genetic Counsellors (2)Board-certified / trained in cancer geneticsMonth 3–6
Quality ManagerNABL / ISO 15189 implementation experienceMonth 6–9
Advisory BoardMedical oncologist, surgical oncologist, pharma biomarker expertFormalise before close
10 — The Ask

₹4.5 Crore seed round.

Heavy capex, lean operating buffer, and a fast path to NABL accreditation and revenue.

Use of Funds₹ Cr%Details
Laboratory capex — build-out + equipment2.9766%Sequencer, extraction, qPCR, IHC, QC suite, LIMS, lab build
NABL, validation, SOPs, legal, insurance0.307%Validation studies, proficiency testing, consultants
Working capital & operating buffer1.2327%12–15 months of operating cash burn
Total4.50100%

What we deliver to investors

Month 8

NABL-accredited in-house lab live

Month 12

20–30 oncologist relationships; 5–8 collection centres

Year 2

₹2.5 Cr+ revenue run-rate

Month 20–22

EBITDA-positive operations

Investor Enquiries

Talk to the founders.

We welcome conversations with seed investors, family offices, and strategic partners in Indian oncology and diagnostics.

Download full pitch deck (.pptx) ↓

Send an enquiry